AIPLA Submits Amicus Brief to Supreme Court in AMP v. Myriad Genetics

by McDonnell Boehnen Hulbert & Berghoff LLP
Contact

AIPLA #1There is a great cultural divide that has been illuminated by the Myriad case (AMP v. Myriad Genetics), between producers of technology and its consumers, governments and non-government organizations such as patient groups who are goal-driven to reduce present costs (especially in healthcare) regardless of future disadvantages, and the more general schism between those who understand science and technology and those who don't.  There is also the problem of bright, educated, ambitious, and motivated graduates of America's best colleges and universities who have the natural propensity of their class and age to think they have better answers than their elders who have actually tackled the problems of investment and commercialization.  This becomes a problem, of course, when many of these folks go into government, resulting in the Justice Department's "magic microscope" as but one example.

Another consequence is that briefs for both sides of the "gene patenting" question repeat the same arguments based on the same policy rationales to come to the same conclusions.  The AIPLA's amicus brief in the Myriad case illustrates the issue.  The brief sets forth the following propositions:

I. MYRIAD'S CLAIMED DNA MOLECULES ARE NOT PRODUCTS OF NATURE
    A. Human DNA Is Complex in Both Structure and Function
    B. Myriad Claims Isolated DNA Molecules, Not Found in Humans, That Can Perform New Functions
II. THE FEDERAL CIRCUIT APPLIED THE CORRECT TEST
    A. Patent Eligibility of Isolated DNA Molecules, Which Are Compositions of Matter, Must Be Analyzed Under the Applicable Precedents
    B. Prometheus Applies to Method Claims, Not to the Isolated DNA Molecule Claims at Issue Here
    C. Myriad's Claims May Not Be Patentable, But That Does Not Make Them Patent-Ineligible Under Section 101
III. PATENT PREEMPTION DOES NOT PRECLUDE THE PATENTABILITY OF THE CLAIMED SUBJECT MATTER
    A. The Importance of Broad Patent Eligibility
    B. The Experimental Use Exception Allows For Some Uses of the Claimed DNA Molecules
IV. CONGRESS HAS RECOGNIZED THE PATENT ELIGIBILITY OF ISOLATED DNA MOLECULES
    A. Moral and Ethical Considerations Are for Congress, Not the Courts

There is not an incorrect statement of the law in any of this, nor the science.  (There are a few aspects that bear closer scrutiny, as set forth below.)  But it is true that the science of DNA does not resemble either the pointedly incorrect analogies set forth by the petitioners (DNA as a kidney, or a leaf, or a mineral) or the equally inapt analogies by courts (such as the distinctions between a tree and a baseball bat or a statue and a piece of marble).  Ignoring the facts makes it easy to misapply the law; indeed, the old aphorism may need to be updated to read "Bad analogies make bad law."  The distinctions set forth in Section I of the AIPLA's brief are not news to anyone who understands the scientific basis of isolated DNA.  But generalist lawyers and judges can be understood (if not forgiven) to have believed that the ways scientists have tried to explain DNA (as a library or a book or a code or software) are in fact what DNA actually is.  "A gene is but a chemical compound, albeit a complex one" is the proper measure of what is encompassed in claims to isolated DNA, and the conflation of the patent-eligible molecule for the patent-ineligible sequence has made it easier for petitioners to convince some judges and the public that patents for human genes are a bad idea.

MyriadNor is the brief incorrect on the law, setting forth the "applicable precedents" of Chakrabarty, Funk Bros., and J.E.M. Ag Supply to support the proposition that isolated human DNA satisfies the requirements for the "hand of man" and new utilities of isolated natural products.  Unfortunately, the matter is before the Court because the patent eligibility of isolated human DNA has not been decided before, despite the 30 years and thousands of patents in this area.  And the brief is also correct that the principles enunciated in Benson, Flook, Diehr, Bilski, and Mayo do not directly apply, as those were method claims embodying laws of nature, not composition or manufacture claims directed to isolated "products of nature."  The brief goes somewhat astray in making this argument categorically, i.e., based on the statutory category of invention rather than, for example, on the differences in scope of the two types of claims.  This is nicely illustrated by the Myriad claims at issue, which are limited to DNA molecules that encode a specific amino acid sequence.  Unlike the broad reach of claims to a "law of nature," Myriad's claims are extremely narrow.  Think:  if a putatively infringing DNA molecule encodes a protein that differs by even a single amino acid, that DNA molecule does not literally infringe.  This point is even sharper when it is recognized that the one amino acid difference could be a valine to isoleucine change, which is equivalent to the addition or subtraction of a single methylene group – (-CH2-) –  in a protein molecule comprising 60,000-100,000 atoms.  Never has so small a change had so large an effect on claim scope, and yet the AIPLA misses the opportunity to inform the Court that petitioners' claims about the scope of preemption occasioned by permitting isolated human DNA to be patented are grossly exaggerated.  Also in this section of the brief the AIPLA appears to agree that Myriad's claims may not even be patentable, a curious position for a brief in favor of patent eligibility.  Mayo showed clearly that the Court believes that its Section 101 jurisprudence is "well established" and a better vehicle for preventing patenting of claims that should not be patented -- why give them a reason to think that Myriad's claims might not be worth the effort?

The brief's section on preemption is where questions are raised about the focus of the brief and its potential vel non for persuasiveness.  First, rather than addressing the argument, the brief takes the position that "broad patent eligibility" is necessary, thereby to a degree conceding to petitioners the point that these claims broadly preempt use of human genes for research.  The brief then posits the existence of an "experimental use exception" for basic research that, frankly, does not exist.  While there are some 19th Century district court cases that support the proposition, for most, the Federal Circuit's decision in Madey v. Duke Univ., 307 F.3d 1351, 1361-62 (Fed. Cir. 2002), foreclosed any such broad protection against patent infringement liability for university research.  This is because the Federal Circuit recognized that university research was not for "philosophical experiments" or "gratifying a philosophical taste, or curiosity, or for mere amusement."  The brief correctly identifies the "safe harbor" provisions of the Hatch-Waxman Act, codified under 35 U.S.C. § 271(e)(1), but while broadly interpreted by the Supreme Court (Medtronic v. Eli Lilly & Co., Merck v. Integra) this is of limited usefulness for most inventions including isolated human DNA.  And the brief's citation of In re Rosuvastatin Calcium Patent Litig., __ F.3d___, 2012 WL 6217356, at *12 (Fed. Cir. Dec. 14, 2012), misses the mark because while "patenting does not deprive the public of the right to experiment with and improve upon the patented subject matter" and "[i]t is not necessary to wait for the patent to expire before the knowledge contained in the patent can be touched," the case does not stand for the proposition that a three-judge panel of the Court sua sponte created a research exception sufficient to protect university research on isolated, patented human DNA.  (It is somewhat amusing that one of the citations set forth in the brief to support the existence of a experimental use exception is L.C. Bruzzone, The Research Exemption: A Proposal, 21 AIPLA Q.J. 52 (1993), which is, on its face, a proposal.)  The better argument, of course, is that there has never been patent infringement litigation against basic research, even by Myriad:  indeed, more than 10,000 research papers have been published since the BRCA gene patents were granted.  This statistic is much more persuasive than an argument that bolsters the proposition that basic science research is at risk of patent infringement liability but for the tenuous existence of a experimental use/research exemption.

Finally, as has been discussed in previous posts, it is a waste of paper to argue to this Court deference to Congress on such matters, particularly when it is inaction, rather than affirmative action, that is the basis for the argument.

Oral argument is set for April 15th, and Patent Docs will be posting on additional amicus briefs in the interim and oral argument in due course.

 

Written by:

McDonnell Boehnen Hulbert & Berghoff LLP
Contact
more
less

McDonnell Boehnen Hulbert & Berghoff LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.
Feedback? Tell us what you think of the new jdsupra.com!